Emergency department experience with tolvaptan in patients with acute heart failure and hyponatremia;Experiencia en el uso de tolvaptán en el servicio de urgencias en pacientes con insuficiencia cardiaca aguda e hiponatremia

Emergencias

Volumn 24, Issue 2, 2012, Pages 126-129

  Llorens, Pere ^a   Lau Cheng, Arturo ^a   Carratalá, José Manuel ^a   Climent, Eduardo ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Acute heart failure; Emergency health services; Hyponatremia; Short stay unit; Tolvaptan

Indexed keywords

EID: 84859131859     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (15)

1. Farmakis D, Filippatos G, Parissis J, Krematinos DTh, Gheorghiade M. Hyponatremia in heart failure. Heart Fail Rev. 2009;14:59-63.
2. Miró Ò, Llorens P, Martín-Sánchez FJ, Herrero P, Pavón J, Pérez-Durá MJ, et al. Short-term prognostic factors in elderly patients seen in emergency department for acute heart failure. Rev Esp Cardiol. 2009;62:757-64.
3. Nodari S, Jao GT, Chiong JR. Clinical utility of tolvaptan in the management of hiponatremia in heart failure patients. Int J Nephrol Renovasc Dis. 2010;3:51-60.
4. Chatterjee K. Hyponatremia in heart failure concluding remarks. Heart Fail Rev. 2009;14:87-8.
5. Llorens P, Miró Ò, Martín Sánchez FJ, Herrero Puente P, Jacob Rodríguez J, Gil V, et al. Manejo de la insuficiencia cardiaca aguda en los servicios de urgencias, emergencias y unidades adscritas. Documento de consenso del Grupo de Insuficiencia Cardiaca Aguda de la Sociedad Española de Medicina de Urgencias y Emergencias (ICA-SEMES). Emergencias. 2011;23:119-39.
6. Goldsmith SR. Current treatment and novel pharmacologic treatment for hiponatremia in congestive heart failure. Am J Cardiol. 2005;95(suppl):14B-23B.
7. Zmily HD, Daifallah S, Ghali JK. Tolvaptan, hiponatremia, and heart failure. Int J Nephrol Renovasc Dis. 2011;4:57-71.
8. Ambrosy A, Goldsmith SR, Gheorghiade M. Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin Pharmacother. 2011;12:961-76.
9. Ho KKL, Anderson KM, Kannel WB, Grosssman W, Levy D. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation. 1993;88:107-15.
10. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Rev Esp Cardiol. 2008;61:1329. e1-1329. e70.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease study group. Ann Intern Med. 1999;130:461-70.
12. Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol. 2007;47:1498-507.
13. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-94.
14. Cyr PL, Slawsky KA, Olchanski N, Krasa HB, Goss TF, Zimmer C, et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health Syst Pharm. 2011;68:328-33.
15. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-5.